Articles

Poll

Podcasts

Slideshows

Videos

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Panelists discuss how patients with resistant hypertension should be referred to specialists after 3 to 6 months of unsuccessful treatment, emphasizing that while primary care providers can manage most hypertension cases, specialists with particular interest and experience are needed for complex cases.

Collaborating in a Multidisciplinary Team to Control Resistant Hypertension

Panelists discuss how resistant hypertension is defined as blood pressure remaining above 130/80 mm Hg despite 3 medications, including a diuretic, affecting 10% to 15% of hypertensive patients, and how to differentiate true resistance from pseudoresistance caused by adherence issues, improper measurement, white coat effect, and interfering medications.

Defining Resistant Hypertension

A panelist discusses how comorbidities like obesity, diabetes, and kidney disease significantly contribute to resistant hypertension through mechanisms including dietary sodium excess, arterial stiffening, and hormonal disruption from the renin-aldosterone system

How Poor Diet and Comorbidities Affect Resistant Hypertension

The Phase 3 HYPERION trial achieved its primary endpoint of lower time to clinical worsening, measured by a variety of related factors.

Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension

A panelist discusses how the underlying causes of resistant hypertension remain largely mysterious, though physicians must screen for secondary causes like cortisol-producing tumors or coarctation of the aorta while recognizing that some patients simply don’t respond to normally effective medications.

Diagnosing Resistant Hypertension: Tools, Triggers, and Screening Tactics

GMRx2 is now the first and only FDA-approved triple combination medication for use as an initial therapy in patients needing multiple drugs to lower blood pressure.

FDA Approves Triple Combination Drug GMRx2 (WIDAPLIK) for Hypertension Treatment

A panelist discusses how resistant hypertension is defined as persistently high blood pressure (>135/85 mm Hg) despite patients being on multiple antihypertensive medications and occurs in approximately 1 in 5 compliant patients.

An Overview of Resistant Hypertension and Prevalence

New research suggests intensive blood pressure management may significantly benefit adults aged 80 and older, challenging previous treatment assumptions.

Lower Blood Pressure May Offer Benefits Even for the Very Elderly

The FDA approves treprostinil inhalation powder, enhancing treatment options for patients with pulmonary arterial hypertension and interstitial lung disease.

FDA Approves Treprostinil Inhalation Powder for PAH, PH-ILD

FDA approves 12.5 mg chlorthalidone tablets, enhancing hypertension treatment options and aligning with clinical guidelines for better patient outcomes.

FDA Approves 12.5 mg Chlorthalidone Tablets for Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.